Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 11/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 17/20 | 0.82 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658065 | 0.92 | GABRA1 (0.86) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6200753 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6199608 | 0.90 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL2660125 | 0.88 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6216804 | 0.85 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL2657699 | 0.85 | GABRA1 (0.74) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL1081801 | 0.84 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6199882 | 0.84 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL6199625 | 0.84 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA2GABRA3 | |
| SCHEMBL2657944 | 0.82 | GABRA1 (0.85) | GABRA1GABRG2GABRB3GABRA2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409488-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-16 | — | — | EP | claimed |
| US-6696444-B2 | NEUROTRANSMITTER ANTAGONISTS COMPRISING COMPOUNDS SUCH AS 4,2'-DIFLUORO-5'-(3-(1-FLUORO-1-METHYLETHYL)IMIDAZO(1,2-B)(1,2 ,4) TRIAZIN-7-YL)BIPHENYL-2-CARBONITRILE, ADMINISTERED FOR THE PROPHYLAXIS OF HEADACHES OR AS ANTICONVULSANTS | MERCK SHARPE & DOHME (GB) | 2004-02-24 | — | — | US | claimed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | claimed |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2003-11-20 | — | — | US | claimed |
| US-6617326-B2 | For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety and convulsions | MERCK SHARP & DOHME LTD. | 2003-09-09 | — | — | US | claimed |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-20 | — | — | US | claimed |
| US-20190134057-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | UNIVERSITAT ZURICH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1409488-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-6696444-B2 | NEUROTRANSMITTER ANTAGONISTS COMPRISING COMPOUNDS SUCH AS 4,2'-DIFLUORO-5'-(3-(1-FLUORO-1-METHYLETHYL)IMIDAZO(1,2-B)(1,2 ,4) TRIAZIN-7-YL)BIPHENYL-2-CARBONITRILE, ADMINISTERED FOR THE PROPHYLAXIS OF HEADACHES OR AS ANTICONVULSANTS | MERCK SHARPE & DOHME (GB) | 2004-02-24 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6617326-B2 | For therapy and prophylaxis of adverse conditions of the central nervous system, including anxiety and convulsions | MERCK SHARP & DOHME LTD. | 2003-09-09 | — | — | US | disclosed |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134057-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | GABRB2, GABRB3, GABRB1 | GABRA1 11/4885GABRG2 8/4885GABRB3 2/4885 |
| US-20030216395-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA3, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 8/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | GABRA1 3/4885GABRG2 14/4885GABRB3 9/4885 |
| US-20030055060-A1 | Imidazo-triazine derivatives as ligands for GABA receptors | GABRA2, GABRA1, GABRA3 | GABRA1 2/4885GABRG2 15/4885GABRB3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.